Recent Updates
Recently added Catalysts

New formulation, Current formulation

Phase 1

Herpes Labialis | Small molecule | Infectious Disease |GSK plc|Last Updated: Aug 31, 2018

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
RandomizedACTIVE_CONTROLLED
Total Trials1
Total Enrollment27
FDA Designations
No designations recorded
Clinical Trials (1)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT00711776Bioequivalence Study of Aciclovir 5% Cream in Japanese Healthy VolunteersPHASE1 COMPLETED 27Apr 10, 2008Aug 17, 2008Aug 31, 20181 Japan
Unlock Drug Trial Details
Study Endpoints
Primary Endpoints
Bioequivalence of Aciclovir amount in keratin layer of the epidermis between Current and New formulation of Aciclovir cream
One day
Secondary Endpoints
To investigate the safety and tolerability of New and Current formulation of Aciclovir Cream 5% following single topical application in healthy Japanese male subjects
One day
Unlock Study Endpoints
Study Design & Arms
AllocationRANDOMIZED
MaskingNONE
ModelSINGLE_GROUP
PurposeTREATMENT
Treatment Arms
ArmTypeDescription
Subjects receiving new formulation in blank test groupEXPERIMENTALEligible subjects will receive acyclovir cream 5 % following single topical application.
Subjects receiving current formulation in blank test groupACTIVE_COMPARATOREligible subjects will receive acyclovir cream 5 % following single topical application.
Subjects receiving new formulation in pre-test groupEXPERIMENTALEligible subjects will receive acyclovir cream 5 % following single topical application.
Subjects receiving current formulation in pre-test groupACTIVE_COMPARATOREligible subjects will receive acyclovir cream 5 % following single topical application.
Subjects receiving new formulation in main-test groupEXPERIMENTALEligible subjects will receive acyclovir cream 5 % following single topical application.
Subjects receiving current formulation in main-test groupACTIVE_COMPARATOREligible subjects will receive acyclovir cream 5 % following single topical application.
Interventions
NameTypeDescription
New formulationDRUGNew formulation of Aciclovir Cream 5% scheduled to be substituted to Current formulation in Japan
Current formulationDRUGCurrent formulation of Aciclovir Cream 5% in Japan
Unlock Study Design Details
Eligibility Criteria
Age Range20 Years — 55 Years
SexMALE
Healthy VolunteersYes
Study Sites1

Inclusion Criteria: * Healthy Japanese adult males between 20 and 55 years of age, inclusive. Healthy subjects are defined as individuals who are free from clinically significant disease as determined by their medical history, physical examination, clinical laboratory examinations, vital sign, 12-...

Countries:Japan
Unlock Eligibility Criteria